Helping the stock's year-to-date gain is the four FDA approvals DexCom received within a 120 day period. These approvals also help the company improve its products' accuracy, Gregg explained.
DexCom is answering unmet needs with "very superior" technologies, he said. One of those technologies comes in the form of SHARE, the company's omni-channel real-time monitoring system.
The Dexcom G4 Platinum receiver allows for continuous monitoring of glucose levels for diabetics. The SHARE system allows for that information to be shared in real time with loved ones using paired devices.
Accuracy is improving as well. DexCom recently drove down its Mean Absolute Relative Difference measurement to 9%, from 13%. This is important, he said, as the company attempts to eliminate finger sticks to measure glucose levels. It is the first and only system to get below a MARD measurement of 10%.
The company plans on expanding its sales force in 2015 and improving its products, Gregg explained. It also plans to continue working with its partners like Johnson & Johnson (JNJ) , Tandem Diabetes (TNDM) , Insulet (PODD) and Asante.
-- Written by Bret Kenwell
TheStreet Ratings team rates DEXCOM INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:
"We rate DEXCOM INC (DXCM) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its disappointing return on equity."
You can view the full analysis from the report here: DXCM Ratings Report